Page 154 - 南京医科大学自然版

第45卷第8期
·1210 · 南 京 医 科 大 学 学 报 2025年8月

Surg Oncol，2022，20：289 LIU L，LUO D. In vitro study on the intervention of alpha⁃
［53］WANG Y，LU J，CHONG X，et al. PD⁃1 antibody camreli⁃ fetoprotein producing gastric carcinoma with GPC3⁃CAR⁃
zumab plus apatinib and SOX as first⁃line treatment in pa⁃ T therapy［J］. Current Immunology，2022，42（1）：25-30
tients with AFP ⁃ producing gastric or gastro ⁃ esophageal ［57］SAHIN U，TÜRECI Ö，MANIKHAS G，et al. FAST：a ran⁃
junction adenocarcinoma（CAP 06）：a multi⁃center，single domised phase Ⅱ study of zolbetuximab（IMAB362）plus
⁃ arm，phase 2 trial［J］. Signal Transduct Target Ther， EOX versus EOX alone for first ⁃ line treatment of ad⁃

2025，10：100 vanced CLDN18.2 ⁃ positive gastric and gastro ⁃ oesopha⁃
［54］DENG T，WANG F，ZHANG L，et al. Combinational zim⁃ geal adenocarcinoma［J］. Ann Oncol，2021，32（5）：609-
berelimab plus lenvatinib and chemotherapy for alpha⁃fe⁃ 619
toprotein elevated，advanced gastric cancer patients（AFP⁃ ［58］LIU S，ZHANG Z，JIANG L，et al. Claudin⁃18.2 mediated
GC）：a phase 1 dose⁃escalation study［J］. Cancer Immu⁃ interaction of gastric cancer cells and cancer⁃associated fi⁃
nol Immunother，2024，73（8）：154 broblasts drives tumor progression［J］. Cell Commun Sig⁃
［55］ZHAO J，LIN L，LUO Y，et al. Optimization of GPC3⁃spe⁃ nal，2024，22：27
cific chimeric antigen receptor structure and its effect on ［59］MEYER T，SANGRO B，MAHIPAL A，et al. Updated data
killing hepatocellular carcinoma cells［J］. Bioengineered， from an ongoing study with ADP⁃A2AFP spear T⁃cells［J］.

2021，12（1）：3674-3683 J Hepatol，2020，73：S910-S911
［56］刘 莉，罗 丹. GPC3⁃CAR⁃T 疗法干预甲胎蛋白阳性 ［收稿日期］ 2025-04-13
胃癌的体外研究［J］. 现代免疫学，2022，42（1）：25-30 （本文编辑：唐 震）

（上接第1193页） ［26］ZHANG Y F，ZHOU C，GUO S，et al. Deep learning algo⁃

prostate cancer：integrating intratumoral and peritumoral rithm⁃based multimodal MRI radiomics and pathomics da⁃
radiomics with clinical and metabolic features［J］. BMC ta improve prediction of bone metastases in primary pros⁃
Med Imaging，2024，24（1）：353 tate cancer［J］. J Cancer Res Clin Oncol，2024，150（2）：
［23］THOMAS J，ATLURI S，ZUCKER I，et al. A multi⁃institu⁃ 78
tional study of 1 111 men with 4K score，multiparametric ［27］HU C H，QIAO X M，HUANG R P，et al. Development
magnetic resonance imaging，and prostate biopsy［J］. Urol and validation of a multimodality model based on whole⁃
Oncol Semin Orig Investig，2023，41（10）：430. e9-430. slide imaging and biparametric MRI for predicting postop⁃
e16 erative biochemical recurrence in prostate cancer［J］. Ra⁃
［24］ZHOU C，ZHANG Y F，GUO S，et al. Multimodal data in⁃ diol Imaging Cancer，2024，6（3）：e230143
tegration for predicting progression risk in castration⁃resis⁃ ［28］NING J，SPIELVOGEL C P，HABERL D，et al. A novel
tant prostate cancer using deep learning：a multicenter ret⁃ assessment of whole ⁃ mount Gleason grading in prostate
rospective study［J］. Front Oncol，2024，14：1287995 cancer to identify candidates for radical prostatectomy：a
［25］GUERRA A，WANG H，ORTON M R，et al. Prediction of machine learning⁃based multiomics study［J］. Theranos⁃
extracapsular extension of prostate cancer by MRI ra⁃ tics，2024，14（12）：4570-4581
diomic signature：a systematic review［J］. Insights Imag⁃ ［收稿日期］ 2025-03-01
ing，2024，15（1）：217 （本文编辑：陈汐敏）